Use of biomarkers and multigene assays in breast cancer

Research output: Contribution to journalArticle

Abstract

All patients with early breast cancer should be classified by subgroup through testing estrogen receptor, progesterone receptor, and HER2 status, with or without Ki-67 proliferation percentage. Genomic expression profiling aids clinical decision-making in most patients, because most are estrogen receptor–positive. The commercially available classifiers are prognostic for distant recurrence in node-negative and also node-positive patients. Patients at genomically low risk have excellent 5-year outcomes with endocrine therapy alone. Some assays also predict for benefit from adjuvant endocrine therapy and chemotherapy in node-negative and node-positive patients, but with varying levels of evidence. Genomic classifiers are also prognostic of late relapse and may predict benefit from extended adjuvant endocrine therapy.

Original languageEnglish (US)
Pages (from-to)676-678
Number of pages3
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume15
Issue number5S
DOIs
StatePublished - May 1 2017

Fingerprint

Biomarkers
Breast Neoplasms
Recurrence
Progesterone Receptors
Estrogen Receptors
Estrogens
Therapeutics
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Use of biomarkers and multigene assays in breast cancer. / Schwartzberg, Lee.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 15, No. 5S, 01.05.2017, p. 676-678.

Research output: Contribution to journalArticle

@article{b32fc3ce87a64d72b9fe9ccd55d3cae5,
title = "Use of biomarkers and multigene assays in breast cancer",
abstract = "All patients with early breast cancer should be classified by subgroup through testing estrogen receptor, progesterone receptor, and HER2 status, with or without Ki-67 proliferation percentage. Genomic expression profiling aids clinical decision-making in most patients, because most are estrogen receptor–positive. The commercially available classifiers are prognostic for distant recurrence in node-negative and also node-positive patients. Patients at genomically low risk have excellent 5-year outcomes with endocrine therapy alone. Some assays also predict for benefit from adjuvant endocrine therapy and chemotherapy in node-negative and node-positive patients, but with varying levels of evidence. Genomic classifiers are also prognostic of late relapse and may predict benefit from extended adjuvant endocrine therapy.",
author = "Lee Schwartzberg",
year = "2017",
month = "5",
day = "1",
doi = "10.6004/jnccn.2017.0070",
language = "English (US)",
volume = "15",
pages = "676--678",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "5S",

}

TY - JOUR

T1 - Use of biomarkers and multigene assays in breast cancer

AU - Schwartzberg, Lee

PY - 2017/5/1

Y1 - 2017/5/1

N2 - All patients with early breast cancer should be classified by subgroup through testing estrogen receptor, progesterone receptor, and HER2 status, with or without Ki-67 proliferation percentage. Genomic expression profiling aids clinical decision-making in most patients, because most are estrogen receptor–positive. The commercially available classifiers are prognostic for distant recurrence in node-negative and also node-positive patients. Patients at genomically low risk have excellent 5-year outcomes with endocrine therapy alone. Some assays also predict for benefit from adjuvant endocrine therapy and chemotherapy in node-negative and node-positive patients, but with varying levels of evidence. Genomic classifiers are also prognostic of late relapse and may predict benefit from extended adjuvant endocrine therapy.

AB - All patients with early breast cancer should be classified by subgroup through testing estrogen receptor, progesterone receptor, and HER2 status, with or without Ki-67 proliferation percentage. Genomic expression profiling aids clinical decision-making in most patients, because most are estrogen receptor–positive. The commercially available classifiers are prognostic for distant recurrence in node-negative and also node-positive patients. Patients at genomically low risk have excellent 5-year outcomes with endocrine therapy alone. Some assays also predict for benefit from adjuvant endocrine therapy and chemotherapy in node-negative and node-positive patients, but with varying levels of evidence. Genomic classifiers are also prognostic of late relapse and may predict benefit from extended adjuvant endocrine therapy.

UR - http://www.scopus.com/inward/record.url?scp=85043355181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043355181&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2017.0070

DO - 10.6004/jnccn.2017.0070

M3 - Article

VL - 15

SP - 676

EP - 678

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 5S

ER -